• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Acute Lymphoblastic Leukemia
Tag:

Acute Lymphoblastic Leukemia

Health

Early life exposure to PFAS associated with common childhood leukemia

by Chief Editor April 27, 2026
written by Chief Editor

The Hidden Risk in Newborns: How ‘Forever Chemicals’ are Shaping the Future of Pediatric Cancer Research

For years, the conversation around PFAS—per- and polyfluoroalkyl substances—has focused on contaminated water systems and industrial runoff. However, a shift in research methodology is revealing a more intimate and concerning connection: the presence of these “forever chemicals” in newborns.

View this post on Instagram about The Hidden Risk, Forever Chemicals
From Instagram — related to The Hidden Risk, Forever Chemicals

Recent research from the University of California, Irvine Joe C. Wen School of Population & Public Health has highlighted a potential link between early-life exposure to PFAS and acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. This discovery is pushing the medical community to rethink how we monitor environmental toxins during the most vulnerable stages of human development.

Did you know? PFAS are used in everything from nonstick cookware and stain-resistant fabrics to food and beverage containers because they resist heat, water, and oil. Because they do not break down easily, they accumulate in the human body over time.

From Environmental Estimates to Direct Biomarkers

One of the most significant trends in this field is the move away from indirect exposure estimates. Previously, researchers might estimate a child’s PFAS exposure by sampling the drinking water in their neighborhood. While useful, this method doesn’t account for the actual “internal dose” a child receives.

In a study published in the Journal of Exposure Science & Environmental Epidemiology, researchers analyzed dried blood spots collected from newborns. This approach provided a direct measurement of what was present in the blood at birth.

From Environmental Estimates to Direct Biomarkers
Los Angeles County Veronica Vieira Wen Public Health

The study looked at children born in Los Angeles County between 2000 and 2015, comparing 125 children diagnosed with acute lymphoblastic leukemia against 219 children without cancer. By capturing data during this critical window, scientists are gaining a far more precise understanding of pediatric oncogenesis.

“This research moves us closer to understanding what babies are exposed to from the highly start by directly measuring PFAS present at birth, rather than estimating exposure from drinking water. By capturing exposures during a critical window of development, we are gaining a clearer picture of how environmental contaminants may contribute to childhood cancer risk.”

— Veronica Vieira, corresponding author, chair and professor of environmental and occupational health at Wen Public Health

The Danger of the ‘Chemical Cocktail’

While many studies focus on a single toxin, future trends in toxicology are shifting toward “combined exposure” analysis. The UC Irvine research found that PFOA and PFOS were the most prevalent PFAS detected in newborn blood.

PFAS exposure during pregnancy and early life

Crucially, the data suggested that the risk of developing leukemia appeared to rise when children were exposed to both chemicals simultaneously. This suggests that the interaction between different PFAS compounds may be more hazardous than any single chemical alone.

This “cocktail effect” is becoming a primary focus for researchers. It implies that regulatory limits based on individual chemicals may be insufficient to protect public health, as they don’t account for the synergistic effects of multiple persistent pollutants.

Pro Tip: To reduce your family’s exposure to PFAS, consider transitioning away from nonstick cookware with PTFE coatings and avoiding water-resistant clothing or stain-proof fabrics when possible.

Expanding the Watchlist: The Unmonitored PFAS

The scope of the PFAS problem is much larger than the few well-known chemicals like PFOA and PFOS. In the recent study, researchers identified 26 additional PFAS compounds in newborn blood, some of which have rarely been studied before.

This points to a looming challenge for public health: the majority of the PFAS class remains largely unmonitored. As industries develop new synthetic alternatives to banned PFAS, these “replacement” chemicals may enter the environment and human tissue without sufficient safety data.

The trend is moving toward “non-targeted analysis,” where scientists search for any and all PFAS compounds rather than looking for a specific, pre-defined list. This comprehensive approach is essential for identifying new risks before they become widespread public health crises.

The Path Toward Population-Level Reduction

While the current research does not prove cause and effect, it adds to a growing body of evidence. This includes previous work by the same team that tracked more than 40,000 California children and linked PFAS in drinking water to increased risks of Wilms tumor and acute myeloid leukemia.

The Path Toward Population-Level Reduction
Forever Chemicals The Hidden Risk

The future of pediatric health will likely depend on two parallel tracks:

  • Enhanced Screening: Integrating environmental biomarker testing into neonatal care to identify high-risk exposures early.
  • Systemic Policy Changes: Moving beyond cleaning up contaminated sites to eliminating the use of these persistent chemicals in consumer products entirely.

As these chemicals are supported by grants from organizations like the National Institutes of Health, the push for stricter regulation and more comprehensive monitoring is expected to accelerate.

Frequently Asked Questions

What are “forever chemicals”?
PFAS (per- and polyfluoroalkyl substances) are synthetic chemicals used for their resistance to heat, water, and oil. They are called “forever chemicals” because they do not break down easily in the environment or the human body.

How do babies obtain exposed to PFAS?
PFAS can be transferred from the environment into the body through contaminated drinking water, food packaging, and everyday household items, and can be present in the blood at birth.

Does this study prove that PFAS cause leukemia?
No. The study shows an association between early PFAS exposure and a higher risk of acute lymphoblastic leukemia, but it does not prove a direct cause-and-effect relationship.

Which PFAS chemicals are the most concerning?
PFOA and PFOS were found at the highest levels in the newborn blood spots analyzed in the study and were associated with increased odds of leukemia.


What are your thoughts on the regulation of PFAS in consumer products? Do you think more newborn screening is necessary? Let us know in the comments below or subscribe to our newsletter for the latest updates in environmental health.

April 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

UIC scientists redesign asparaginase to minimize leukemia treatment side effects

by Chief Editor February 1, 2025
written by Chief Editor

Revolutionizing Pediatric Leukemia: A Safer, Effective Treatment on the Horizon

Recent advances at the University of Illinois Chicago have the medical community buzzing with excitement as scientists rewrite the treatment playbook for pediatric leukemia. By redesigning a key treatment known as asparaginase, researchers aim to eradicate severe side effects and widen treatment applicability. This breakthrough could not only transform leukemia care but also venture into new cancer territories.

Understanding the Innovation

Asparaginase has been a staple in leukemia therapy since its FDA approval in the 1970s. While effective, its severe side effects, including blood clots and liver damage, have limited its use. Researchers at UIC, led by Arnon Lavie, set out to reshape this therapy. By creating a novel form of asparaginase through protein engineering, they’ve enhanced its therapeutic effects while significantly reducing toxicity. This redesigned drug promises a safer journey for those battling pediatric leukemia.

From Lab to Lifesaving Solutions

In a promising study published in *Cancer Letters*, the UIC team demonstrated the new compound’s ability to destroy leukemia cells in mice without the common side effects of traditional asparaginase. Remarkably, this enzyme also exhibited anticancer potential against other serious diseases like melanoma and liver cancer. This versatility heralds a future where one treatment could address multiple cancer types.

Origins and Innovations

Tracing back to its roots in the 1950s, the redesigned enzyme owes its innovation to the guinea pig, the natural source of the original asparaginase. By leveraging similarities between guinea pig and human enzymes, researchers managed to “humanize” the new enzyme, minimizing immune response risks. This adaptation also fortuitously extended the drug’s half-life, reducing the treatment’s frequency and burden on patients.

Paving the Way for Clinical Trials

With positive preliminary results, the path to clinical trials is becoming clear. UIC’s Enzyme by Design, supported by nearly $4 million in funding, is leading the charge in toxicity, pharmacokinetic, and manufacturing studies to meet FDA approval for human trials. Approximately ten years of research, development, and support has brought this academic endeavor closer to becoming a viable clinical solution.

Looking Ahead: Future Trends and Potential

Cross-Cancer Potential

The ability of this reformulated asparaginase to effectively target various cancers beyond leukemia could redefine cancer treatment protocols. By expanding its scope, this enzyme not only addresses the most common pediatric leukemia but may also provide a potent weapon against solid tumors known to be asparagine-dependent. The success in preclinical melanoma and liver cancer models indicates a broader application spectrum.

Reduced Treatment Burden

One of the highlighted benefits of this new treatment is its reduced administration frequency, a game-changer for patient quality of life. Traditional asparaginase requires multiple infusions per week, leading to compliance challenges and increased patient burden. With the new compound’s extended half-life, patients could expect longer intervals between treatments, reducing hospital visits and improving overall treatment experience.

Fundamental Shifts in Pharmaceutical Interest

Typically, the pharmaceutical industry hesitates to back research with high risk. However, the efforts to de-risk this novel asparaginase, thereby making it appealing to pharmaceutical companies, are setting a precedent for future research endeavors. This could encourage more industry partnerships in innovating and developing therapies with reduced adverse effects.

Key Insights and FAQs

Did You Know?

The enzyme was originally discovered in guinea pigs, a fact that provided a key insights leading to its redesign. By understanding these origins, scientists were able to align its properties more closely with human enzymes, drastically reducing immune reactions.

Pro Tips

When keeping up with advancements in cancer treatment, pay attention to promising research funding and partnerships, as these often indicate significant progress and potential market readiness.

Reader’s Corner

What do you hope to see in the future of cancer treatment? Share your thoughts and ideas in the comments!

Frequently Asked Questions (FAQ)

What is asparaginase and how does it work?
Asparaginase is an enzyme that depletes the amino acid asparagine, essential for some cancer cells’ survival, thus starving and killing them.

Why was a new form of asparaginase needed?
The original drug had severe side effects and limited usability due to a strong immune response and short half-life.

When could this new treatment be available to patients?
While the current focus is on clinical trials, expected timelines suggest potential availability within a few years, pending FDA approval.

Explore More: Read more about UIC’s research breakthroughs.

Stay Informed and Engaged

Your insights, experiences, and questions enrich our conversation about the future of cancer treatment. Subscribe to our newsletter to stay abreast of the latest in cancer treatment research and breakthrough technologies.

This content provides an insightful and engaging exploration of recent advancements in leukemia treatment, leveraging the potential future impacts both on pediatric care and beyond. The strategic incorporation of subheadings, real-life examples, FAQs, and interactive elements promotes engagement and SEO performance, suitable for embedding in a WordPress post.

February 1, 2025 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • China Slams Japan and EU Over South China Sea and Taiwan Strait Remarks at UN

    April 28, 2026
  • Bell Labs’ Michael Eggleston on Nokia’s research into topological quantum computing

    April 28, 2026
  • Countries Boycott Eurovision Broadcasts Over Israel’s Participation

    April 28, 2026
  • Latvia Bans Three Russian Citizens Including Sergey Lavrov’s Daughter

    April 28, 2026
  • Taylor Swift Registreert Beeld en Geluid Tegen AI-Misbruik

    April 28, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World